Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PAX5 encodes a member of the paired box (PAX) family of transcription factors.
Showing 10 out of 242 products:
Human Monoclonal PAX5 Primary Antibody for ELISA, WB - ABIN969552
Coyaud, Struski, Prade, Familiades, Eichner, Quelen, Bousquet, Mugneret, Talmant, Pages, Lefebvre, Penther, Lippert, Nadal, Taviaux, Poppe, Luquet, Baranger, Eclache, Radford, Barin, Mozziconacci et al.: Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. ... in Blood 2010
Show all 2 Pubmed References
Human Monoclonal PAX5 Primary Antibody for IHC, ELISA - ABIN1098104
OBrien, Morin, Ouellette, Robichaud: The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. in Cancer research 2011
Show all 2 Pubmed References
Human Polyclonal PAX5 Primary Antibody for ELISA, WB - ABIN249618
Adams, Dörfler, Aguzzi, Kozmik, Urbánek, Maurer-Fogy, Busslinger: Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. in Genes & development 1992
The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia hs been reported.
this study demonstrates a role for the AHR (show AHR Antibodies) in regulating human B cell development, and it suggests that transcriptional alterations of PAX5 by the AHR (show AHR Antibodies) are involved in the underlying mechanism
These findings suggested that pax5 is critically important for the proliferation and survival of pre-B cells.
a mechanism of transcriptional regulation mediated by p27 (show PAK2 Antibodies), Pax5, and PCAF (show KAT2B Antibodies)
Data show that paired box gene 5 (B-cell lineage specific activator) protein (Pax-5) induces E-cadherin (show CDH1 Antibodies) expression in breast cancer cells.
a new function of PAX5 in regulating RIP1 (show UQCRFS1 Antibodies) and RIP2 (show ARHGEF28 Antibodies) activation, which is at least involved in chemotherapeutic drug resistance in B-lymphoproliferative disorders, is reported.
PAX5-KIDINS220 (show KIDINS220 Antibodies) fusion is associated with Philadelphia-like acute lymphoblastic leukemia.
this study shows that Pax5 expression is lower in antibody-secreting cells than in naive B cells or plasmablasts
The histological observations suggested that the patients represent diverse cases of NHL (show RTEL1 Antibodies) like mature B-cell type, mature T-cell type and high grade diffuse B-cell type NHL (show RTEL1 Antibodies). The findings indicate that patients with NHL (show RTEL1 Antibodies) may also be analyzed for status of PAX5, CD19 (show CD19 Antibodies) and ZAP70 (show ZAP70 Antibodies), and their transcriptional and post-translational variants for the differential diagnosis of NHL (show RTEL1 Antibodies) and therapy.
B cell receptor signaling component, SYK (show SYK Antibodies), caused PAX5 tyrosine phosphorylation in vitro and in cells. Transcriptional repression on the BLIMP1 (show PRDM1 Antibodies) promoter by PAX5 was attenuated by this phosphorylation.
Pax5 transcription factor cooperates in patterning the Xenopus brain.
identify Pax5 and cyclin D1 (show CCND1 Antibodies) as Zfp521 (show ZNF521 Antibodies) target genes
Together with similar observations made in human PAX5-ETV6 (show ETV6 Antibodies)(+) B-ALLs, these data identified PAX5-ETV6 (show ETV6 Antibodies) fusion as a potent oncoprotein that drives B-cell leukemia development.
PAX5 was found to be an epigenetically inactivated tumor suppressor that inhibited non-small-cell lung proliferation and metastasis, through down-regulating the beta-catenin (show CTNNB1 Antibodies) pathway and up-regulating GADD45G (show GADD45G Antibodies) expression.
Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in mantle cell lymphoma independent of CCND1 (show CCND1 Antibodies).
Spleen-specific isoform of Pax5 and Ataxin-7 (show ATXN7 Antibodies) can be considered as spleen-specific unique molecular markers for the evaluation of splenomegaly and lympho-proliferative disorders.
Pax5 and Ebf1 (show EBF1 Antibodies) collaborate to modulate the transcriptional response to Notch (show NOTCH1 Antibodies) signaling, and their combined heterozygous loss allows for T-lineage conversion of B cell progenitors.
a dramatic increase in the frequency of pro-B cell leukemia was observed in mice with combined heterozygous mutations in the Ebf1 (show EBF1 Antibodies) and Pax5 genes, revealing a synergistic effect of combined dose reduction of these proteins
These results show that in contrast to simple Pax5 haploinsufficiency, multiple sequential alterations targeting lymphoid development are central to leukemogenesis and contribute to the arrest in lymphoid maturation characteristic of ALL.
miR (show MLXIP Antibodies)-155 inhibits PU.1 expression, leading to Pax5 down-regulation and the initiation of the plasma cell differentiation pathway.
restoring endogenous Pax5 expression in established B-ALL triggers immunophenotypic maturation and durable disease remission by engaging a transcriptional program reminiscent of normal B-cell differentiation
pax5 works in conjunction with fgf3 (show FGF3 Antibodies) and pax2a to establish and/or maintain the utricular macula and is essential for vestibular function.
This gene encodes a member of the paired box (PAX) family of transcription factors. The central feature of this gene family is a novel, highly conserved DNA-binding motif, known as the paired box. PAX proteins are important regulators in early development, and alterations in the expression of their genes are thought to contribute to neoplastic transformation. This gene encodes the B-cell lineage specific activator protein that is expressed at early, but not late stages of B-cell differentiation. Its expression has also been detected in developing CNS and testis and so the encoded protein may also play a role in neural development and spermatogenesis. This gene is located at 9p13, which is involved in t(9\;14)(p13\;q32) translocations recurring in small lymphocytic lymphomas of the plasmacytoid subtype, and in derived large-cell lymphomas. This translocation brings the potent E-mu enhancer of the IgH gene into close proximity of the PAX5 promoter, suggesting that the deregulation of transcription of this gene contributes to the pathogenesis of these lymphomas. Alternatively spliced transcript variants encoding different isoforms have been described but their biological validity has not been determined.
paired box 5
, paired box gene 5 (B-cell lineage specific activator)
, paired box protein Pax-5
, paired box protein Pax-5-like
, B-cell lineage specific activator
, paired box homeotic gene 5
, paired domain gene 5
, transcription factor PAX 5
, B-cell-specific transcription factor
, Pax5 variant 1
, Pax5 variant 2
, No isthmus protein